Ferry A.L.M. Eskens
About
Ferry A.L.M. Eskens is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Ferry A.L.M. Eskens has authored 161 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Oncology, 60 papers in Pulmonary and Respiratory Medicine and 40 papers in Molecular Biology. Recurrent topics in Ferry A.L.M. Eskens's work include Cancer Treatment and Pharmacology (31 papers), Colorectal Cancer Treatments and Studies (29 papers) and Gastric Cancer Management and Outcomes (20 papers). Ferry A.L.M. Eskens is often cited by papers focused on Cancer Treatment and Pharmacology (31 papers), Colorectal Cancer Treatments and Studies (29 papers) and Gastric Cancer Management and Outcomes (20 papers). Ferry A.L.M. Eskens collaborates with scholars based in Netherlands, United States and United Kingdom. Ferry A.L.M. Eskens's co-authors include Jaap Verweij, P Hinnen, Ronald Hoekstra, Maja J.A. de Jonge, Ate van der Gaast, Stefan Sleijfer, Leni van Doorn, Alex Sparreboom, Elisabeth G.E. de Vries and Erik A.C. Wiemer and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Ferry A.L.M. Eskens
159 papers receiving 6.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ferry A.L.M. Eskens Netherlands | 43 | 2.9k | 2.6k | 1.5k | 1.2k | 694 | 161 | 6.4k | ||
| Erika Martinelli Italy | 33 | 2.1k 0.7× | 1.8k 0.7× | 1.2k 0.8× | 805 0.7× | 981 1.4× | 109 | 4.4k | ||
| Teresa Troiani Italy | 42 | 3.6k 1.3× | 2.4k 0.9× | 2.0k 1.3× | 1.1k 0.9× | 298 0.4× | 183 | 5.9k | ||
| Dirk Strumberg Germany | 42 | 3.1k 1.1× | 3.5k 1.4× | 1.6k 1.1× | 1.2k 1.0× | 698 1.0× | 141 | 7.4k | ||
| Carolyn D. Britten United States | 36 | 3.0k 1.1× | 2.4k 0.9× | 1.5k 1.0× | 624 0.5× | 417 0.6× | 96 | 5.6k | ||
| Kazuko Sakai Japan | 41 | 2.7k 1.0× | 2.0k 0.8× | 2.3k 1.6× | 1.3k 1.0× | 289 0.4× | 245 | 5.4k | ||
| Nilofer S. Azad United States | 41 | 3.8k 1.3× | 2.3k 0.9× | 1.4k 0.9× | 1.3k 1.0× | 393 0.6× | 205 | 6.3k | ||
| Alexander Laird United States | 32 | 1.7k 0.6× | 2.7k 1.0× | 1.2k 0.8× | 745 0.6× | 743 1.1× | 97 | 4.9k | ||
| M. E. Scheulen Germany | 36 | 2.6k 0.9× | 2.3k 0.9× | 1.2k 0.8× | 734 0.6× | 390 0.6× | 178 | 5.5k | ||
| Ferdinando De Vita Italy | 43 | 3.4k 1.2× | 2.0k 0.7× | 2.2k 1.5× | 1.0k 0.8× | 266 0.4× | 207 | 6.0k | ||
| Allen Lee Cohn United States | 38 | 4.7k 1.6× | 1.5k 0.6× | 2.4k 1.6× | 1.3k 1.0× | 1.2k 1.7× | 159 | 6.9k |
Countries citing papers authored by Ferry A.L.M. Eskens
Since
Specialization
Citations
This map shows the geographic impact of Ferry A.L.M. Eskens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ferry A.L.M. Eskens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ferry A.L.M. Eskens more than expected).
Fields of papers citing papers by Ferry A.L.M. Eskens
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ferry A.L.M. Eskens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ferry A.L.M. Eskens. The network helps show where Ferry A.L.M. Eskens may publish in the future.
Co-authorship network of co-authors of Ferry A.L.M. Eskens
This figure shows the co-authorship network connecting the top 25 collaborators of Ferry A.L.M. Eskens. A scholar is included among the top collaborators of Ferry A.L.M. Eskens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ferry A.L.M. Eskens. Ferry A.L.M. Eskens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Doorn-Khosrovani, Sahar Barjesteh van Waalwijk van, Hans Timmer, Karin Verkerk, et al.. (2024). 1550P Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence. Annals of Oncology. 35. S943–S944.
2.
Lenz, Heinz‐Josef, Guillem Argilés, Maja J.A. de Jonge, et al.. (2024). A phase I dose-escalation study of LRP5/6 antagonist BI 905677 in patients with advanced solid tumors. ESMO Open. 9(11). 103729–103729.
3.
Zwan, Jan Maarten van der, Stefan A.W. Bouwense, M. Wouter Dercksen, et al.. (2022). Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study. European Journal of Cancer. 172. 252–263.
4.
Hamid, Omid, Alberto Chiappori, John A. Thompson, et al.. (2022). First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 10(10). e005471–e005471.
5.
Jones, Robin L., César Serrano, Margaret von Mehren, et al.. (2021). Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. European Journal of Cancer. 145. 132–142.
6.
Burgmans, Mark C., Daphne D. D. Rietbergen, Minneke J. Coenraad, et al.. (2021). Liver Decompensation as Late Complication in HCC Patients with Long-Term Response following Selective Internal Radiation Therapy. Cancers. 13(21). 5427–5427.
7.
Atrafi, Florence, Ruben A.G. van Eerden, Esther Oomen‐de Hoop, et al.. (2020). Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors. Clinical Cancer Research. 26(14). 3537–3545.
8.
IJzendoorn, David G.P. van, Stefan Sleijfer, Hans Gelderblom, et al.. (2018). Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma. Clinical Cancer Research. 24(11). 2678–2687.
9.
Aerts, Joachim G.J.V., Pauline L. de Goeje, Robin Cornelissen, et al.. (2017). Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human. Clinical Cancer Research. 24(4). 766–776.
10.
Benson, Al B., Igor Kišš, John Bridgewater, et al.. (2016). BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer. Clinical Cancer Research. 22(20). 5058–5067.
11.
Tabernero, Josep, Robin M.J.M. van Geel, Tormod Kyrre Guren, et al.. (2016). O-026 Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC): phase 2 results. Annals of Oncology. 27. ii127–ii127.
12.
Lolkema, Martijn P., Hilde Bohets, Hendrik‐Tobias Arkenau, et al.. (2015). The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation. Clinical Cancer Research. 21(10). 2297–2304.
13.
Graan, Anne‐Joy M. de, Laure Elens, Jason A. Sprowl, et al.. (2013). CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity. Clinical Cancer Research. 19(12). 3316–3324.
14.
Eskens, Ferry A.L.M., Francisco Javier Ramos, Herman Burger, et al.. (2013). Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 19(22). 6296–6304.
15.
Banerji, Udai, Leni van Doorn, Dionysis Papadatos-Pastos, et al.. (2012). A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors. Clinical Cancer Research. 18(9). 2687–2694.
16.
Marshall, John L., Jimmy Hwang, Ferry A.L.M. Eskens, et al.. (2012). A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Investigational New Drugs. 31(2). 399–408.
17.
Eskens, Ferry A.L.M., Maja J.A. de Jonge, Pankaj Bhargava, et al.. (2011). Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors. Clinical Cancer Research. 17(22). 7156–7163.
18.
Baird, Richard D., Jos Kitzen, Paul A. Clarke, et al.. (2009). Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. Molecular Cancer Therapeutics. 8(6). 1430–1437.
19.
Mom, Constantijne H., Jaap Verweij, Corina N.A.M. Oldenhuis, et al.. (2009). Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study. Clinical Cancer Research. 15(17). 5584–5590.
20.
Eskens, Ferry A.L.M., C.J.A. Punt, & C.A.H.H.V.M. Verhagen. (1996). Trombo-embolische complicaties van centraal-veneuze katheters. Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank. 140(46). 2302–2302.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Erika Martinelli Breakdown of academic impact, for papers by Teresa Troiani Breakdown of academic impact, for papers by Dirk Strumberg Breakdown of academic impact, for papers by Carolyn D. Britten Breakdown of academic impact, for papers by Kazuko Sakai Breakdown of academic impact, for papers by Nilofer S. Azad Breakdown of academic impact, for papers by Alexander Laird Breakdown of academic impact, for papers by M. E. Scheulen Breakdown of academic impact, for papers by Ferdinando De Vita Breakdown of academic impact, for papers by Allen Lee Cohn